Mostrar el registro sencillo del ítem

dc.rights.licenseopenen_US
dc.contributor.authorLAYCOCK, Katherine
dc.contributor.authorTECHNAU, Karl-Gunter
dc.contributor.authorLELO, Patricia
dc.contributor.authorJANTARABENJAKUL, Watsamon
dc.contributor.authorYONABA, Caroline
dc.contributor.authorPINTO, Jorge
dc.contributor.authorMENSER, Michael
dc.contributor.authorMARURI, Fernanda
dc.contributor.authorODHIAMBO, Francesca
dc.contributor.authorRAMBIKI, Ethel
dc.contributor.authorBABAKAZO, Pelagie
dc.contributor.authorVAN LAM, Nguyen
dc.contributor.authorFOLQUET, Madeleine
dc.contributor.authorMACHADO, Daisy Maria
dc.contributor.authorKALEMA, Nelson
dc.contributor.authorMUULA, Guy
dc.contributor.authorBRAZIER, Ellen
dc.contributor.authorDINH QUI, Nguyen
dc.contributor.authorDAME, Joycelyn
dc.contributor.authorLUQUE, Marco Tulio
dc.contributor.authorSEMEERE, Aggrey
dc.contributor.authorELEY, Brian
dc.contributor.authorYOTEBIENG, Marcel
dc.contributor.authorKARIMINIA, Azar
dc.contributor.authorROUZIER, Vanessa
dc.contributor.authorBYAKWAGA, Helen
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorMARCY, Olivier
dc.contributor.authorENANE, Leslie A
dc.date.accessioned2025-07-04T14:28:47Z
dc.date.available2025-07-04T14:28:47Z
dc.date.issued2025-05-28
dc.identifier.issn2048-7207en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/207221
dc.description.abstractEnBACKGROUND: Tuberculosis (TB) remains a leading cause of morbidity and mortality for children living with HIV (CLHIV), with gaps in TB screening, diagnostics, management, and TB preventive therapy (TPT). We investigated reported practices in these domains at sites caring for CLHIV in low- and middle-income countries (LMICs) within the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. METHODS: We implemented a site survey during September 2020-February 2021, querying pre-pandemic practices. This analysis included sites in LMICs providing care for CLHIV that diagnosed TB in 2019. We analyzed responses using descriptive statistics and assessed regional differences using Fisher's exact or chi-square tests. RESULTS: Of 238 IeDEA sites, 227 (95%) responded and 135 met inclusion criteria. Most (90%) reported screening for TB at HIV care enrollment. Access to diagnostics varied significantly by region, including for nucleic acid amplification testing (NAAT, range 67-100%), mycobacterial culture (range 43-83%), and drug susceptibility testing (range 30-82%) (p<0.001). On-site TB treatment was high (90%). Reported stock-outs occurred for isoniazid (23/116, 20%) and other TB medications (11/114, 9.6%, range 0-33%, p=0.008). TPT provision ranged 50-100% (p<0.001). Six months of isoniazid was the most common TPT regimen for children (88%). Shorter TPT regimens were uncommon (0.9-2.8%), as were regimens for multidrug-resistant TB exposure (4.6%). CONCLUSIONS: Overall reported availability of NAAT and integrated TB/HIV treatment for CLHIV cared for at these IeDEA sites in LMICs is encouraging but varies by context. Heterogeneous implementation gaps remain-particularly for drug susceptibility testing, TPT delivery and TPT regimens-which successful outcomes for CLHIV, warranting continued close attention over time and as global TB care guidelines and services evolve.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enHIV
dc.subject.enTB
dc.subject.enTB Preventive Therapy
dc.subject.enDiagnostic Access
dc.subject.enPediatrics
dc.title.enTuberculosis diagnosis, treatment, and prevention services for children living with HIV in low- and middle-income countries: a multiregional site survey
dc.title.alternativeJ Pediatric Infect Dis Socen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/jpids/piaf050en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed40425522en_US
bordeaux.journalJournal of the Pediatric Infectious Diseases Societyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDNational Institutes of Healthen_US
bordeaux.identifier.funderIDNational Institute of Allergy and Infectious Diseasesen_US
bordeaux.identifier.funderIDEunice Kennedy Shriver National Institute of Child Health and Human Developmenten_US
bordeaux.identifier.funderIDNational Cancer Instituteen_US
bordeaux.identifier.funderIDNational Institute of Mental Healthen_US
bordeaux.identifier.funderIDNational Institute on Drug Abuseen_US
bordeaux.identifier.funderIDNational Institute on Alcohol Abuse and Alcoholismen_US
bordeaux.identifier.funderIDNational Heart, Lung, and Blood Instituteen_US
bordeaux.identifier.funderIDFogarty International Centeren_US
bordeaux.identifier.funderIDNational Institute of Diabetes and Digestive and Kidney Diseasesen_US
bordeaux.identifier.funderIDInstitut de Recherche pour le Développementen_US
hal.identifierhal-05144942
hal.version1
hal.date.transferred2025-07-04T14:28:52Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Journal%20of%20the%20Pediatric%20Infectious%20Diseases%20Society&amp;rft.date=2025-05-28&amp;rft.eissn=2048-7207&amp;rft.issn=2048-7207&amp;rft.au=LAYCOCK,%20Katherine&amp;TECHNAU,%20Karl-Gunter&amp;LELO,%20Patricia&amp;JANTARABENJAKUL,%20Watsamon&amp;YONABA,%20Caroline&amp;rft.genre=article


Archivos en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem